Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07108036 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Anktiva in Patients With Long Covid-19.
A Phase 2 study, sponsored by ImmunityBio.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT07108036 is a Phase 2 study that is actively recruiting participants, run by ImmunityBio. The registered enrollment target is 20 participants.
The verdict
NCT07108036, a Phase 2 study, is actively recruiting participants, sponsored by ImmunityBio.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study will test the safety and tolerability of Anktiva in patients with Long Covid. Eligible patients will receive up to 2 doses of Anktiva and have follow-up exams and tests.
Interventions
- DRUG N-803 (IL-15 Superagonist)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-11-14 |
| Est. Completion | 2026-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07108036
The ClinicalTrials.gov registry entry for NCT07108036 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunityBio, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which N-803 (IL-15 Superagonist) is the first listed.
NCT07108036 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07108036 about?
NCT07108036 is a clinical study titled "A Study to Assess Anktiva in Patients With Long Covid-19.". This study will test the safety and tolerability of Anktiva in patients with Long Covid. Eligible patients will receive up to 2 doses of Anktiva and have follow-up exams and tests.
What is the current status of trial NCT07108036?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-11-14. Estimated completion is 2026-10.
What interventions are being tested in trial NCT07108036?
The interventions under investigation include: N-803 (IL-15 Superagonist) (DRUG).
Who is sponsoring clinical trial NCT07108036?
This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.